Search

Even eight years after its Today Show cameo, Given Imaging's PillCam sounds like something out of a Bond film. The Israeli company is about to launch the third generation of [...]

Consumer advertising of prescription drugs is effective. It's controversial--reviled, even. It influences the medical decision-making of lay people with little medical knowledge--while educating them about diseases and treatment options they [...]

Sanofi came into 2012 staring down at the steepest patent cliff in the industry. Plavix, for which Sanofi's share of 2011 global sales was $2.6 billion, lost US exclusivity in [...]

The patient support site has become a standard element of the drug marketing armory--offering patients C a mix of disease info, lifestyle tips, tools to manage their illness, maybe even [...]

Imagine a patient with type 2 diabetes plugs a port little larger than a thumb drive into her iPhone and inserts a test strip. Up pops a three-digit number--her blood-glucose [...]

The prescription drug ads of tomorrow won't interrupt our favorite TV show to suggest that we ask our doctor about some pill to treat a condition we probably don't have, [...]

Rheumatoid arthritis is a mysterious progressive autoimmune disease which strikes mostly women of child-bearing age, often suddenly, causing them to suffer wracking joint pain that renders them unable to perform [...]

In April, FDA approved Roche Diagnostics' Cobas HPV test (below), which uses Polymerase Chain Reaction technology to screen for 14 high-risk HPV types, including types 16 and 18, which are [...]

MM&M takes a look at the top 20 drug manufacturers and breaks down the sales data by company, prescription drugs and therapeutic class. We also track total promotional spend, professional [...]

Rest in peace, Digger, Abe and the Beaver. Soldier on, Lunesta Moth, Nasonex Bee and VESIcare pipe people. You may be the last of a dying breed, flitting across our [...]

Merck's Vree is a Swiss army knife of an app for type 2 diabetes patients. Launched in September for iPhone and iPad. it lets them track their blood sugar, medications, [...]

With the dust beginning to settle on a wave of massive patent expirations--and massive sales force downsizings that came with them--a new commercial model is starting to come into focus. [...]

Adherence is a pricey problem. Patients failing to take their meds as directed or at all costs us anywhere from $170 billion to more than a quarter-trillion in added healthcare [...]

The cartoon ladies looked as though they might have leapt from the pages of The New Yorker, but here they were, in Ladies' Home Journal, hawking the world's first orthopedic [...]

Just a few years ago, the news that pharma ad spend was up a mere 2% would have been greeted with horror in adland. But that was before--before a dizzying [...]

Perhaps no large pharmaceutical company is so well positioned to survive the approaching patent cliff as Novartis. And it's no accident that the Swiss giant is in such good shape [...]

Though better known for his jump shot, the president is also a chess player, habitually thinking several moves ahead and hard to faze. It shows in his healthcare game. [ILLUSTRATION [...]

Certified and accredited CME has undergone a sea-change in recent years, with policies now in place emphasizing quality and leaving little room for bias (not that you'd know it, for [...]

Consumer marketers aren't exactly turning off the TV just yet, but with budgets tightening, blockbusters going off-patent and DTC TV in disrepute, they are spending more time on YouTube and [...]

The prospect of unified Democratic control in Washington is cause for some unease in an industry that has, for years, aligned closely with Republicans. Indeed, President-elect Obama and congressional Democrats [...]

[ILLUSTRATION OMITTED] His healthcare plan calls for allowing drug reimportation and direct government negotiation of drug prices with companies that, he says, 'benefit most from the status quo, and in [...]

[ILLUSTRATION OMITTED] Pharmaceutical companies seem to be holding the line on grants for now, but with intense pressure from officials, academia and increasingly, the medical community, not to mention their [...]

[ILLUSTRATION OMITTED] Direct-to-consumer advertising is set for a sea-change, as marketers embrace more targeted and digital-heavy media plans to push more modest products and fewer mega-blockbusters through--not that you'd know [...]

[ILLUSTRATION OMITTED] When the going got tough, Merck got back to basics. Today, only a few years after a toxic combination of high-profile drug failures and the Vioxx safety debacle [...]

[ILLUSTRATIONS OMITTED] A cautious FDA sweating product safety issues and going slow on new approvals. An election year in which healthcare tops the agenda. Increased oversight, increasingly demanding payors and [...]

[ILLUSTRATION OMITTED] As big pharma binges on biotechs to feed anemic pipelines, at least one major player isn't getting indigestion. Wyeth has been in the biotech game for more than [...]

Innovative new oncology drugs and an increase in prescribing volume due to Medicare Part D drove a rebound in US prescription drug growth of 8.3% for 2006, up from 5.4% [...]

It's been 10 years since it was first 'time for Claritin,' and DTC advertising as we know it was born. A decade after the FDA issued its draft guidance on [...]

Hearings, hearings and more hearings on the dastardly doings of the pharmaceutical industry will be the order of the day for a Democratic Congress, Washington insiders say. While congressional Dems [...]

With sales forces feeling the pinch from physicians, Merck is turning to technology to realize efficiencies and help reps hit their targets. The firm has deployed tablet PCs to 5,000 [...]

The medical advertising and communications behemoth Publicis Healthcare Communications Group saw strong organic growth this year, expanding its business with core clients Sanofi-Aventis and AstraZeneca as it rebranded one of [...]

Consumer drug advertising is back--if it was ever really gone--nattily attired in a starched lab coat. After an apocalyptic post-Vioxx pause, when many marketers folded their wallets, held their breaths [...]

While pharma's biggest players continue to wear their poker faces in the game of sales-force contraction, Wyeth has boldly laid its cards on the table, announcing a creative solution to [...]

Analysts are hopeful that both companies and consumers will come out ahead with the implementation of Medicare Part D, but the realignment will take all parties into uncharted waters. For [...]

National TV advertising may be losing some of its luster, but disease-specific cable and local broadcasts beckon, offering advertisers a cheaper and more targeted means of reaching patient communities. Leading [...]

DTC OUTLOOK Pharmaceutical companies are facing increasing pressure from Washington, the media, the public and from fellow pharma chiefs to advertise to consumers in a more responsible way, conveying risks [...]

The crisis over the safety of COX-2 inhibitors is almost certainly the most severe to hit the industry in decades. At stake are the reputations not only of Merck and [...]

Much of Big Pharma breathed a sigh of relief at the news of President Bush's re-election, as Kerry and Edwards, two of the industry's harshest critics, were sent back to [...]

'Most companies, when they're launching a product in primary care, will advertise to PAs and NPs,' says Carla Duryee, who heads marketing to midlevel practitioners for Sanofi-Aventis. 'But very few [...]

Pharmaceutical advertising doesn't exactly have the wildest reputation within the marketing business, but you could hardly want for a more exciting environment these days, as agencies buffeted by wave upon [...]

What really keeps the custodians of the world's best-selling prescription drug awake at night? It's not so much the competition, nor is it patent exclusivity. What worries the relationship marketers [...]

Genentech's head of corporate relations. Mary Stutts, reckons the drug industry could do with fewer celebrity endorsers and more heroes. That's why Napoleone 'Napo' Ferrara is the new face of [...]

Thomson's $135 million sale of its Medical Economics, veterinary and dental units has sent ripples through the sluggish medical publishing industry, giving Advanstar greater entree with advertisers through several of [...]

In an ugly season for medical advertising, a wave of intra-agency consolidation has roiled the agency world and sent smaller shops reeling as the big boys band together. Matthew Arnold [...]

Direct marketing has yet to live up to its potential in the pharmaceutical sector, but as the burden of pharmaceutical marketers shifts from acquiring patients to improving compliance and physicians [...]

Despite mounting evidence that DTC advertising provides a public health benefit by educating consumers, critics won't be quieted. Matthew Arnold looks at how the industry might better mold its message [...]

Determining the return on internet marketing investment is one of marketers' toughest challenges. Senior reporter Matthew Arnold looks at this issue, as well as the potential of e-detailing and consolidation [...]

It's survived a tortuous yearlong journey through Washington's legislative sausage mill, a nationwide storm of colorful protests, 'Death Panels,' a high-wire Supreme Court case and a close presidential election. Whatever [...]

In 2011, digital media shifted from the horizon to the gravitational center of the marketing mix. Everybody's there all the time, doctors and patients alike, and increasingly on their phones [...]

Boehringer Ingelheim: 126 years old. Privately owned. German. Should be a fusty, conservative sort of company, content to play it safe and leave the innovation to its publicly traded peers, [...]